Other · developed by Krystal Biotech
KB304 is a genetically modified herpes simplex type 1 virus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06724900 | Phase 1/2 | Wrinkles in Decolletage | Active not recruiting | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Décolleté WrinklesPigmentationWrinkles in Decolletage
Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →